HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

NCT02569320 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma

Interventions

DRUG: Dexamethasone
DRUG: HDAC Inhibitor AR-42
OTHER: Laboratory Biomarker Analysis
DRUG: Pomalidomide

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]